Literature DB >> 12928148

Increased influence of genetic variation on PON1 activity in neonates.

Jia Chen1, Madhu Kumar, Wendy Chan, Gertrud Berkowitz, James G Wetmur.   

Abstract

PON1 (paraoxonase-1) detoxifies organophosphates by cleavage of active oxons before they have a chance to inhibit cholinesterases. The corresponding gene PON1 has common polymorphisms in both the promoter (-909, -162, -108) and the coding region (L55M, Q192R). The five PON1 genotypes were determined for maternal blood (n= 402) and cord blood (n= 229) as part of a study of the effects of organophosphate pesticide exposure on infant growth and neurodevelopment. PON1 enzymatic activities were determined for a majority of subjects. The population contained Caucasians, Caribbean Hispanics, and African Americans. PON1 activity was strongly dependent upon the promoter alleles in both maternal and cord blood. For example, PON1 activities for position -108CC, CT, and TT mothers were 146, 128, and 109 arylesterase U/mL (analysis of variance, p< 0.0001), whereas the same PON1 activities for the respective cord bloods were 49.0, 32.4, and 23.2 U/mL (p < 0.0001). Compared with adults, neonates had lower PON1 activity, implying reduced capacity to detoxify organophosphates. In addition there was a larger difference in activity between genotype groups in neonates than in adults. Because the five polymorphisms in PON1 occur in a short stretch of DNA, they were tested for linkage disequilibrium (LD). Significant LD was found among all three promoter polymorphisms as well as between promoter polymorphisms and L55M, with the strongest LD for Caucasians and the weakest for African Americans. The Caribbean Hispanics fall between these two groups. Surprisingly, significant LD also was observed between the promoter polymorphisms and C311S in PON2. LD between the promoter polymorphisms and Q192R was not significant.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12928148      PMCID: PMC1241633          DOI: 10.1289/ehp.6105

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN: 0091-6765            Impact factor:   9.031


  37 in total

1.  Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes.

Authors:  M C Garin; R W James; P Dussoix; H Blanché; P Passa; P Froguel; J Ruiz
Journal:  J Clin Invest       Date:  1997-01-01       Impact factor: 14.808

2.  The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin.

Authors:  H G Davies; R J Richter; M Keifer; C A Broomfield; J Sowalla; C E Furlong
Journal:  Nat Genet       Date:  1996-11       Impact factor: 38.330

3.  Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities.

Authors:  K N Gan; A Smolen; H W Eckerson; B N La Du
Journal:  Drug Metab Dispos       Date:  1991 Jan-Feb       Impact factor: 3.922

4.  Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/arylesterase.

Authors:  C E Furlong; R J Richter; S L Seidel; L G Costa; A G Motulsky
Journal:  Anal Biochem       Date:  1989-08-01       Impact factor: 3.365

5.  The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family.

Authors:  S L Primo-Parmo; R C Sorenson; J Teiber; B N La Du
Journal:  Genomics       Date:  1996-05-01       Impact factor: 5.736

6.  Neurochemical and neurobehavioral effects of repeated gestational exposure to chlorpyrifos in maternal and developing rats.

Authors:  S M Chanda; C N Pope
Journal:  Pharmacol Biochem Behav       Date:  1996-04       Impact factor: 3.533

7.  Structural organization of the human PON1 gene.

Authors:  J B Clendenning; R Humbert; E D Green; C Wood; D Traver; C E Furlong
Journal:  Genomics       Date:  1996-08-01       Impact factor: 5.736

8.  The molecular basis of the human serum paraoxonase activity polymorphism.

Authors:  R Humbert; D A Adler; C M Disteche; C Hassett; C J Omiecinski; C E Furlong
Journal:  Nat Genet       Date:  1993-01       Impact factor: 38.330

9.  Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes.

Authors:  S Adkins; K N Gan; M Mody; B N La Du
Journal:  Am J Hum Genet       Date:  1993-03       Impact factor: 11.025

10.  Interrelationships of serum paraoxonase, serum lipids and apolipoproteins in normal pregnancy. A longitudinal study.

Authors:  A C Roy; D F Loke; N Saha; O A Viegas; J S Tay; S S Ratnam
Journal:  Gynecol Obstet Invest       Date:  1994       Impact factor: 2.031

View more
  45 in total

1.  Comparing genetic ancestry and self-reported race/ethnicity in a multiethnic population in New York City.

Authors:  Yin Leng Lee; Susan Teitelbaum; Mary S Wolff; James G Wetmur; Jia Chen
Journal:  J Genet       Date:  2010-12       Impact factor: 1.166

2.  Time course of organochlorine pesticides and polychlorinated biphenyls in breast-feeding mothers throughout the first 10 months of lactation in Tunisia.

Authors:  Soukaina Ennaceur; Mohamed Ridha Driss
Journal:  Environ Monit Assess       Date:  2012-05-29       Impact factor: 2.513

3.  PON1 multitasks to protect health.

Authors:  Janice E Chambers
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-27       Impact factor: 11.205

Review 4.  Recent progress in the genetics and epigenetics of paraoxonase: why it is relevant to children's environmental health.

Authors:  Nina Holland; Daneida Lizarraga; Karen Huen
Journal:  Curr Opin Pediatr       Date:  2015-04       Impact factor: 2.856

5.  Population pharmacokinetic model of canrenone after intravenous administration of potassium canrenoate to paediatric patients.

Authors:  Maysa Suyagh; Ahmed F Hawwa; Paul S Collier; Jeffrey S Millership; Prashant Kole; Muriel Millar; Mike D Shields; Henry L Halliday; James C McElnay
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

6.  Improving cost-effectiveness of epidemiological studies via designed missingness strategies.

Authors:  Warren J Strauss; Louise Ryan; Michele Morara; Nicole Iroz-Elardo; Mark Davis; Matthew Cupp; Marcia G Nishioka; James Quackenboss; Warren Galke; Haluk Ozkaynak; Peter Scheidt
Journal:  Stat Med       Date:  2010-06-15       Impact factor: 2.373

Review 7.  Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity.

Authors:  Lucio G Costa; Gennaro Giordano; Toby B Cole; Judit Marsillach; Clement E Furlong
Journal:  Toxicology       Date:  2012-07-31       Impact factor: 4.221

8.  Developmental changes in PON1 enzyme activity in young children and effects of PON1 polymorphisms.

Authors:  Karen Huen; Kim Harley; Jordan Brooks; Alan Hubbard; Asa Bradman; Brenda Eskenazi; Nina Holland
Journal:  Environ Health Perspect       Date:  2009-06-09       Impact factor: 9.031

9.  Racial differences in paraoxonase-1 (PON1): a factor in the health of southerners?

Authors:  Kimberly A Davis; J Allen Crow; Howard W Chambers; Edward C Meek; Janice E Chambers
Journal:  Environ Health Perspect       Date:  2009-03-12       Impact factor: 9.031

10.  Childhood brain tumors, residential insecticide exposure, and pesticide metabolism genes.

Authors:  Susan Searles Nielsen; Roberta McKean-Cowdin; Federico M Farin; Elizabeth A Holly; Susan Preston-Martin; Beth A Mueller
Journal:  Environ Health Perspect       Date:  2010-01       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.